Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019

Pharmacoepidemiology and Drug Safety(2022)10.1002/pds.5411Source: DataRank Database

Trends in the use of disease‐modifying therapies among reproductive‐aged women with multiple sclerosis in the United States from 2010 to 2019 is a research paper published in Pharmacoepidemiology and Drug Safety (2022). On theSindex it has a DataRank of 0. It has been cited 9 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access9 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 1.23)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Alan C. Kinlaw ORCID,Michele Jönsson Funk ORCID,Virginia Pate ORCID,Jennifer L. Lund ORCID,Emilie D. Duchesneau ORCID

Live enrichment

PubMed:35088492 PMC:PMC10331629 OpenAlex:https://openalex.org/W4210478146

NCATS NIH HHS

Grant: UL1 TR002489

NCI NIH HHS

Grant: T32 CA116339

National Institutes of Health

Grant: 5T32CA116339-14

Cancer Care Quality Training Program

National Institutes of Health

Grant: 3UL1TR002489-02S1

North Carolina Translational and Clinical Science Institute (NC TraCS)

National Center for Advancing Translational Sciences

National Institutes of Health

FWCI

1.23

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

greenLicense: Wiley Online Library User Agreement

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10331629/pdf/nihms-1908620.pdf

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5411

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/pds.5411

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10331629

Fields of Study

Multiple Sclerosis Research StudiesPregnancy and Medication ImpactReproductive System and Pregnancy03 medical and health sciences0302 clinical medicineAdolescentAdultFemaleFingolimod HydrochlorideGlatiramer AcetateHumansImmunosuppressive AgentsInterferon-betaMultiple SclerosisUnited StatesYoung Adult

MeSH Terms

Glatiramer AcetateFingolimod HydrochlorideAdolescentAdultFemaleHumansImmunosuppressive AgentsMultiple SclerosisUnited StatesInterferon-betaYoung Adult

Keywords

MedicineFingolimodTeriflunomideGlatiramer acetateNatalizumabMultiple sclerosisInternal medicineDiseasePediatricsImmunologyWomen's HealthDrug UtilizationDimethyl FumarateDisease-modifying TherapiesAdultAdolescentFingolimod HydrochlorideInterferon-betaUnited StatesYoung AdultHumansFemaleImmunosuppressive Agents

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being